UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2114-10
Program Prior Authorization – Medical Necessity
Medication Albenza (albendazole), Emverm (mebendazole)
P&T Approval Date 11/2016, 3/2017, 6/2017, 6/2018, 5/2019, 4/2020, 5/2021, 5/2022,
6/2023, 8/2024
Effective Date 11/1/2024
1. Background:
Albenza is indicated for the treatment of parenchymal neurocysticercosis due to active lesions
caused by larval forms of the pork tapeworm, Taenia solium. Albenza is also indicated for the
treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of
the dog tapeworm, Echinococcus granulosus.
Emverm is indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura
(whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common
hookworm) and Necator americanus (American hookworm) in single or mixed infections.
CDC guidelines recommend use in several other parasitic infections.
2. Coverage Criteriaa:
A. Enterobius vermicularis (pinworm)
1. Albenza or Emverm will be approved based on both of the following:
a. Diagnosis of Enterobius vermicularis (pinworm)
-AND-
b. History of failure, contraindication or intolerance to over-the-counter pyrantel
pamoate
Authorization will be issued for one month.
B. Taenia solium and Taenia saginata (Taeniasis or Cysticercosis/Neurocysticercosis)
1. Albenza will be approved based on the following criterion:
a. Diagnosis of Taeniasis or Cysticercosis/Neurocysticercosis
Authorization will be issued for six months.
C. Echinococcosis (Tapeworm)
1. Albenza or Emverm will be approved based on the following criterion:
© 2024 UnitedHealthcare Services, Inc.
1
a. Diagnosis of Hydatid Disease [Echinococcosis (Tapeworm)]
Authorization will be issued for six months.
D. Ancylostoma/Necatoriasis (Hookworm)
1. Emverm will be approved based on the following criterion:
a. Diagnosis of Ancylostoma/Necatoriasis (Hookworm)
Authorization will be issued for one month.
2. Albenza will be approved based on the following criterion:
a. Diagnosis of Ancylostoma/Necatoriasis (Hookworm)
Authorization will be issued for six months.
E. Ascariasis (Roundworm)
1. Albenza or Emverm will be approved based on the following criterion:
a. Diagnosis of Ascariasis (Roundworm)
Authorization will be issued for one month.
F. Toxocariasis (Roundworm)
1. Albenza or Emverm will be approved based on the following criterion:
a. Diagnosis of Toxocariasis (Roundworm)
Authorization will be issued for one month.
G. Trichinellosis
1. Albenza or Emverm will be approved based on the following criterion:
a. Diagnosis of Trichinellosis
Authorization will be issued for one month.
H. Trichuriasis (Whipworm)
1. Albenza or Emverm will be approved based on the following criterion:
a. Diagnosis of Trichuriasis (Whipworm)
Authorization will be issued for one month.
© 2024 UnitedHealthcare Services, Inc.
2
I. Capillariasis
1. Albenza or Emverm will be approved based on the following criterion:
a. Diagnosis of Capillariasis
Authorization will be issued for one month.
J. Baylisascaris
1. Albenza or Emverm will be approved based on the following criterion:
a. Diagnosis of Baylisascaris
Authorization will be issued for one month.
K. Clonorchiasis (Liver flukes)
1. Albenza will be approved based on the following criterion:
a. Diagnosis of Clonorchiasis
Authorization will be issued for one month.
L. Gnathostomiasis
1. Albenza will be approved based on the following criterion:
a. Diagnosis of Gnathostomiasis
Authorization will be issued for one month.
M. Strongyloidiasis
1. Albenza will be approved based on the following criterion:
a. Diagnosis of Strongyloidiasis
Authorization will be issued for one month.
N. Loiasis
1. Albenza will be approved based on the following criterion:
a. Diagnosis of Loiasis
Authorization will be issued for one month.
© 2024 UnitedHealthcare Services, Inc.
3
O. Opisthorchiasis
1. Albenza will be approved based on the following criterion:
a. Diagnosis of Opisthorchiasis
Authorization will be issued for one month.
P. Anisakiasis
1. Albenza will be approved based on the following criterion:
a. Diagnosis of Anisakiasis
Authorization will be issued for one month.
Q. Microsporidiosis
1. Albenza will be approved based on the following criterion:
a. Diagnosis of Microsporidiosis not caused by Enterocytozoon bieneusi or Vittaforma
corneae.
Authorization will be issued for twelve months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. CDC treatment guidelines. http://www.cdc.gov./parasites. Accessed July 2024.
2. Albendazole [package insert]. Piscataway, NJ: Camber Pharmaceuticals, Inc; November
2022.
3. Emverm [package insert]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; August 2021.
4. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and
Adolescents with HIV. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-
and-adolescent-opportunistic-infections/microsporidiosis. Accessed July 2024.
© 2024 UnitedHealthcare Services, Inc.
4
Program Prior Authorization – Medical Necessity – Anthelmintics
Change Control
11/2016 New program.
3/2017 Updated background. Incorporated CDC and FDA labeled indications.
Updated authorization time based on CDC and FDA recommendations.
6/2017 Added Albenza as an approvable drug for Mansonella perstans
(Filariasis). State mandate reference language updated.
6/2018 Annual review. References updated.
5/2019 Annual review. Added Albenza for Clonorchiasis, Gnathostomiasis,
Strongyloidiasis per CDC treatment guidelines. Removed Albenza for
Mansonella perstans per CDC treatment guidelines. Updated
references.
4/2020 Annual review. Added Albenza for Loa loa, Opisthorchis per CDC
guidelines. Removed Emverm and Vermox for Mansonella perstans.
5/2021 Annual review. Removed Vermox from program due to product
discontinuation. Updated references.
5/2022 Annual review. Changed Ancylostoma/Necatoriasis authorization to six
months per CDC recommendation for Albenza. Formatting changes.
Updated references.
6/2023 Annual review. Added Albenza for Anisakiasis and Microsporidiosis
per CDC and NIH guidelines, respectively. Updated references.
8/2024 Annual review. Clarified spelling of Opisthorchiasis.
© 2024 UnitedHealthcare Services, Inc.
5